Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	4.89M 4.35M 4.03M 3.65M 6.87M 463M 6.97M 48.4M 18.99M 242M 18.32M 17.94M 773M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.4M 10.57M 9.57M 18M 1.21B 18.26M 127M 49.75M 634M 48M 47M 2.03B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/04/20	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/04/20	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
31/03/20	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/03/20	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/03/20	Bidding Procedure Approved for Aradigm Corporation	CI
21/02/20	Motion for Asset Sale Filed by Aradigm Corporation	CI
21/02/20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/11/19	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
31/10/19	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
22/10/19	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/07/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

16/06/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/06/20	ARADIGM CORP : Other Events (form 8-K)	AQ
30/04/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/04/20	ARADIGM CORP : Other Events (form 8-K)	AQ
06/04/20	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Aradigm Corporation Stock

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news: Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	702K
WUXI APPTEC CO., LTD.	+0.79%	-6.46%	+52.86%	+71.34%	65.83B
LONZA GROUP AG	+1.92%	+8.89%	+12.90%	+82.75%	51.87B
ARGENX SE	+6.91%	+6.41%	+9.61%	+73.07%	51.2B
IQVIA HOLDINGS INC.	+0.74%	+2.15%	+30.95%	+43.43%	43.76B
BEONE MEDICINES AG	+3.87%	+9.73%	+21.52%	+142.33%	42.09B
REVOLUTION MEDICINES, INC.	+7.91%	+1.34%	+263.31%	+577.76%	39.04B
CELLTRION, INC.	-0.40%	+9.42%	+18.44%	+59.06%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+4.62%	+24.20%	+31.02%	22.8B
Average	+2.79%	+1.13%	+52.90%	+121.07%	37.58B
Weighted average by Cap.	+3.05%	+0.62%	+51.69%	+122.72%

	2016	2017
Net sales	195K 174K 161K 146K 274K 18.48M 278K 1.93M 758K 9.66M 731K 716K 30.86M	14.46M 12.88M 11.94M 10.82M 20.34M 1.37B 20.64M 143M 56.23M 717M 54.26M 53.12M 2.29B
Net income	-32.94M -29.34M -27.19M -24.63M -46.32M -3.12B -46.99M -326M -128M -1.63B -124M -121M -5.21B	-10.7M -9.53M -8.84M -8M -15.05M -1.01B -15.27M -106M -41.62M -531M -40.15M -39.32M -1.69B
Net Debt	-9.37M -8.35M -7.74M -7.01M -13.18M -888M -13.37M -92.85M -36.43M -465M -35.15M -34.42M -1.48B	7.91M 7.05M 6.53M 5.92M 11.13M 750M 11.29M 78.39M 30.76M 392M 29.68M 29.06M 1.25B